Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receiving Iomab-B Presented at 2021 SNMMI Virtual ConferencePRNewsWire • 06/15/21
Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer CellsBenzinga • 06/03/21
Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual MeetingPRNewsWire • 06/03/21
Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AMLPRNewsWire • 03/25/21
Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell TherapyPRNewsWire • 03/24/21
Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARCPRNewsWire • 03/11/21
Actinium Announces Participation in H.C. Wainwright Global Life Sciences ConferencePRNewsWire • 03/02/21
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual MeetingPRNewsWire • 02/11/21
Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor ConferencePRNewsWire • 01/20/21
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted RadiotherapiesPRNewsWire • 01/13/21
Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trialPRNewsWire • 12/29/20
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 12/23/20
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 12/17/20
Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should KnowZacks Investment Research • 12/09/20
Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual MeetingPRNewsWire • 12/07/20
Actinium Pharmaceuticals: Our Bullish View Is Intact On Promising Early Stage ResultsSeeking Alpha • 12/04/20
Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent ActivityPRNewsWire • 11/23/20
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 11/20/20
Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical AffairsPRNewsWire • 11/19/20